Literature DB >> 27202160

Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy Naïve Patients.

L Dearden1, I Majer2, B Heeg2, J Liwing3, K Sandstrom3, J Diels4.   

Abstract

Entities:  

Year:  2014        PMID： 27202160     DOI： 10.1016/j.jval.2014.08.2170

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  3 in total

1.  Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Authors:  Peter Nash; Iain B McInnes; Philip J Mease; Howard Thom; Matthias Hunger; Andreas Karabis; Kunal Gandhi; Shephard Mpofu; Steffen M Jugl
Journal:  Rheumatol Ther       Date:  2018-03-31

2.  Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.

Authors:  Jon P Fryzek; Heidi Reichert; Nicholas Summers; Lindsay Townes; Robert Deuson; Dominik D Alexander; Jackie Vanderpuye-Orgle
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240

3.  Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.

Authors:  Walter P Maksymowych; Vibeke Strand; Peter Nash; Yusuf Yazici; Howard Thom; Matthias Hunger; Chrysostomos Kalyvas; Kunal K Gandhi; Brian Porter; Steffen M Jugl
Journal:  Eur J Rheumatol       Date:  2018-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.